A 52-year-old morbidly obese man with chronic obstructive pulmonary disease complains of shortness of breath at rest and dyspnea on exertion.
In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.
Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.
Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD
Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.
The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.
The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.
Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.
Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.
Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.
Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.
In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.
A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.
The American Diabetes Association has responded with "deep" concern to recent hemoglobin A1c target guidance authored by the American College of Physicians.
For patients with type 2 diabetes, pioglitazone use may be associated with decreases in both cardiovascular and noncardiovascular mortality.
T2D may play a protective role against the development of aortic diseases through structural changes in the aortic wall.
In patients with diabetes who had an acute myocardial infarction, the acute-to-chronic glycemic ratio was a better predictor of mortality compared with baseline glycemia levels.
The expanded use of TIMI Risk Score for Secondary Prevention in patients with T2D may be helpful to predict risk for CV events accurately.
Renin-independent aldosteronism, and possibly mineralocorticoid receptor activation increase risk for hypertension.
Glucagon-like peptide-1 receptor agonists can reduce major adverse cardiovascular events in patients with type 2 diabetes.
Patients with visit-to-visit variability of fasting plasma glucose may have a higher risk of developing cardiovascular disease and all-cause mortality.
The FDA has approved semaglutide injection for the treatment of type 2 diabetes in adults.
The Cardiology Advisor Articles
- FDA Reports Combination Hypertension Treatment Discontinued
- Automated Detection of Atrial Fibrillation Through Smartwatch Technology
- Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D
- Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes
- Machine Learning Shows Potential in Diagnosing Myocardial Infarction in Patients With Chest Pain
- Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time
- Pioglitazone Lowers Cardiovascular, Noncardiovascular Mortality in Diabetes
- Peripheral Artery Disease, DVT Risk May Increase With Varicose Veins
- Cardiorespiratory Fitness May Improve Executive Function in Mild Cognitive Impairment
- Preventing Chemotherapy-Related Cardiotoxicity in Breast Cancer
- Patent Foramen Ovale Characteristics May Predict Benefits of PFO Closure
- Low-Dose Triple Combo Therapy Effective in Hypertension
- Blood Pressure, Glucose Levels Worsened From the Great Recession
- Acute MI Hospital Mortality During Transcatheter Cardiovascular Therapeutics Meeting Dates
- A 64-Year-Old Woman With Colorectal Cancer Presents to ED With Severe Chest Pain